The fourth-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off in late January when bellwether Johnson & Johnson reported strong fourth-quarter results, beating estimates for earnings and sales. While most of the pharma bigwigs are slated to report their ear ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Insights - Acadia Pharmaceuticals anticipates a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its marketing application for trofinetide to treat Rett syndrome [1][2] Company Overview - Acadia was informed of a negative trend vote on its marketing application for trofinetide, which may delay potential approval in the European Union [2] - The company plans to seek a re-examination of the CHMP opinion once it is formally adopted [2] Product Information - Trofinetide is intended for treating Rett syndrome, a rare neurodevelopmental disorder affecting approximately one in 10,000-15,000 female births globally [3] - The FDA approved trofinetide for treating Rett syndrome in adults and pediatric patients aged two years and older in 2023, marketed as Daybue in the United States [4] Financial Performance - Acadia's shares have increased by 8.6% over the past six months, while the industry has seen a rally of 18.8% [5] - The company expects long-term growth from its products Nuplazid and Daybue, targeting combined net sales of $1.7 billion by 2028, with approximately $1 billion from Nuplazid and $700 million from Daybue [8][9] Market Position - Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, with patent protection until 2038 [10] - In the first nine months of 2025, Nuplazid generated $505.7 million in sales, reflecting a 13% year-over-year increase [10] - Daybue has also shown promising sales, with $281.8 million in sales during the first nine months of 2025, up 12% year-over-year [11] New Product Launch - The FDA recently approved Daybue Stix, an oral solution for treating Rett syndrome, which will be launched in a limited capacity in Q1 2026, followed by broader availability in Q2 2026 [12][13]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Acadia Pharmaceuticals (ACAD) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 50.00%.For the most ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earni ...

Core Insights - ACADIA Pharmaceuticals aims to become a leading company in neurological and rare diseases, focusing on delivering meaningful innovations to underserved patients [2][3] Neurological Franchise - The momentum of NUPLAZID is expected to continue driving growth this year and beyond [3] - The company is advancing several pipeline candidates, including a new 5-HT2A agonist, remlifanserin (formerly ACP-204) [3] - Ongoing Phase II programs include ACP-211, a deuterated R-ketamine for major depressive disorder, and potential expansions into essential tremor with ACP-711 and tardive dyskinesia with ACP-271 [3]

Financial Performance - Acadia Pharmaceuticals anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance[6] Corporate Events - The company presented at the J.P. Morgan Healthcare Conference on January 13, 2026[6] - A corporate slide presentation was posted on the company's investor website[6] Regulatory Filings - The report is filed under the Securities Exchange Act of 1934[8] - The company has not elected to use the extended transition period for new financial accounting standards[5] - No emerging growth company status was indicated in the filing[5] - The report includes a Regulation FD disclosure[7] - The financial statements and exhibits are part of the filing[9] - The report was signed by Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer & Secretary[13] Stock Information - Acadia Pharmaceuticals is listed on The Nasdaq Stock Market under the symbol ACAD[5]

Summary of ACADIA Pharmaceuticals FY Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Industry**: Neurological and Rare Diseases - **Conference**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 Core Points and Arguments Company Mission and Strategy - ACADIA aims to deliver meaningful innovation to underserved patients with neurological and rare diseases, focusing on first-in-class or best-in-class products [2][4] - The company is advancing its pipeline with several candidates, including Remlifansirin (5-HT2A agonist) and ACP-211 (deuterated ketamine) for major depressive disorder [3][4] Pipeline Developments - **Neurological Franchise**: - NUPLAZID is expected to continue its momentum, with sales projected to reach $1 billion by 2028 [6][11] - Remlifansirin is anticipated to have a peak sales potential of $4 billion across indications [6] - Upcoming milestones include the initiation of phase two studies for ACP-271 and results for Remlifansirin expected between August and October 2026 [5][25] - **Rare Disease Franchise**: - DAYBUE is projected to achieve $700 million in global sales by 2028, driven by the launch of DAYBUE Sticks and expansion into the EU [14][30] - The company has treated over 2,000 patients with DAYBUE since its launch in 2023, with a 55% persistency rate at 12 months [13] Market Opportunities - There are approximately 1 million Parkinson's patients in the U.S., with 50% expected to develop hallucinations or delusions, presenting a significant market opportunity for NUPLAZID [10] - The company sees a potential growth opportunity in treating essential tremor, which affects about 7 million patients in the U.S. [23] Commercial Strategy - ACADIA plans to increase its commercial field force for NUPLAZID by 30% and leverage AI for better targeting and engagement [12][8] - The company is focused on expanding its presence in international markets, with DAYBUE already approved in three markets and anticipated approval in Europe [9][27] Financial Projections - Combined net sales for NUPLAZID and DAYBUE are projected to reach $1.7 billion by 2028 [6][30] - The company expects to see an uptick in operating expenses due to investments in commercial expansion and pipeline development [32][33] Additional Important Content - The company is committed to utilizing AI across various functions, including R&D and regulatory processes, to enhance efficiency and decision-making [7][9] - ACADIA is exploring business development opportunities in rare diseases beyond neurology, with a focus on late-stage products [34][35] - The company emphasizes the importance of patient-centric approaches in its clinical trials and product development [18][21] This summary encapsulates the key points discussed during the conference call, highlighting ACADIA Pharmaceuticals' strategic direction, pipeline developments, market opportunities, and financial outlook.

J.P. Morgan Healthcare Conference January 13, 2026 Catherine Owen Adams Chief Executive Officer 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," ...

Core Insights - Investors in the Medical - Biomedical and Genetics sector may consider Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD) as potential undervalued stocks [1] Group 1: Company Rankings - Fortrea Holdings Inc. has a Zacks Rank of 2 (Buy), while Acadia Pharmaceuticals has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for FTRE [3] Group 2: Valuation Metrics - FTRE has a forward P/E ratio of 22.95, significantly lower than ACAD's forward P/E of 38.66, suggesting FTRE may be undervalued [5] - The PEG ratio for FTRE is 0.51, compared to ACAD's PEG ratio of 7.12, indicating FTRE's expected earnings growth is more favorable [5] - FTRE's P/B ratio is 2.72, while ACAD's P/B ratio is 4.94, further supporting the notion that FTRE is more attractively valued [6] - FTRE has earned a Value grade of B, whereas ACAD has a Value grade of C, reinforcing FTRE's position as the better option for value investors [6]